Derek Gumm

Mr. Gumm’s experience includes advising :

• Amplitude in its US$1.8 billion direct listing
• Clarify Health in its acquisition of Embedded Healthcare
• CooperCompanies in its acquisition of Cook Medical’s Reproductive Health business
• Evernote in its acquisition by Bending Spoons
• Extensiv in connection with a US$80 million senior secured loan from Runway Growth Capital
• Francisco Partners on financing in connection with SatixFy’s US$813 million SPAC transaction
• Headspace in its merger with Ginger to create Headspace Health
• IDEAYA Biosciences, Inc. in its US$80 million follow-on public offering
• Imago BioSciences in its US$1.4 billion acquisition by Merck
• John Deere in its US$250 million acquisition of Bear Flag Robotics
• Khosla Ventures Acquisition Co. II in its merger with Nextdoor to make Nextdoor a publicly listed company
• Laminar, Inc. in its US$400 million acquisition by Johnson & Johnson Medtech
• Pionyr Immunotherapeutics in its US$43 million acquisition by Ikena Oncology 
• Prysm Collective in its acquisition by NEP Group to create NEP Virtual Studios
• Reddit, Inc. in its US$748 million initial public offering
• Revolution Medicines in its US$230 million and US$300 million follow-on public offerings
• Rhythm Pharmaceuticals, Inc. in a global licensing agreement with LG Chem
• Seres Therapeutics in its license agreement with Nestlé Health Science to jointly commercialize SER-109, Seres’ investigational oral microbiome therapeutic for recurrent Clostridium difficile infection (CDI), in the United States and Canada
• ShapeTX with respect to its collaboration with Otsuka to develop novel AAV gene therapies for ocular diseases
• Staked Securely, Inc. in its sale to Payward (dba Kraken)
• Starry Group Holdings in its US$290 million chapter 11 debt restructuring
• Thumbtack in its US$275 million investment
• TLM in its acquisition by Endava
• The underwriters in Chinook Therapeutic’s US$105 million follow-on public offering
• The underwriters in HashiCorp’s US$1.2 billion initial public offering
• The underwriters in Twist Biosciences’ US$250 million upsized public offering
• Vaxcyte in its US$500 million follow-on public offering
• Virgin Orbit in its chapter 11 restructuring